These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 37675102)

  • 1. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Benjamin DJ; Hsu R
    Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
    Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
    Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
    Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
    Peng J; Sridhar S; Siefker-Radtke AO; Selvarajah S; Jiang DM
    Curr Treat Options Oncol; 2022 Sep; 23(9):1269-1287. PubMed ID: 35962938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
    Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
    Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
    Roubal K; Myint ZW; Kolesar JM
    Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.
    Casadei C; Dizman N; Schepisi G; Cursano MC; Basso U; Santini D; Pal SK; De Giorgi U
    Ther Adv Med Oncol; 2019; 11():1758835919890285. PubMed ID: 31803255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
    N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
    Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
    Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma.
    Benjamin DJ; Mar N; Rezazadeh Kalebasty A
    Clin Med Insights Oncol; 2022; 16():11795549221126252. PubMed ID: 36186672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 15. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
    Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
    Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma.
    Sayegh N; Tripathi N; Agarwal N; Swami U
    Onco Targets Ther; 2022; 15():1047-1055. PubMed ID: 36186154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
    Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
    Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Therapy for Metastatic Urothelial Carcinoma.
    Nadal R; Clara JA; Valderrama BP; Bellmunt J
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
    Katoh M; Loriot Y; Brandi G; Tavolari S; Wainberg ZA; Katoh M
    Nat Rev Clin Oncol; 2024 Apr; 21(4):312-329. PubMed ID: 38424198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.